One company currently benefiting from the global Covid 19 crisis is the Swiss company Zur Rose and its subsidiary DocMorris. The Zur Rose Group is expecting a balanced result for 2020, partly because the current share of mail order business in the Rx segment is one percent, but it can be increased significantly in the future. For 2021, the Swiss group of companies then expects an increase in turnover of around eight percent, after deducting all early investments in various technologies in the field of digitalisation, including the mail order of medicines and digital health services. According to Zur Rose, the adjusted Ebitda target margin will then be three billion Swiss francs. The positive effects of the coronavirus are not yet included in the calculation. With the introduction of the ePrescription, the OTC business is likely to shift in favour of prescription drugs, combined with sales growth of about 10 percent. DocMorris is already testing the new technology, which links doctors, pharmacists and patients, in model projects. Good news is also coming from France, where the dispatch of over-the-counter medicines is to be relaxed. Zur Rose is not only benefiting from the effects of the coronavirus, but also from early investments in three technology development centres in Berlin, Winterthur and Barcelona, which will stimulate the digital transformation of the mail order business, as growth of up to 60 percent is possible in individual segments. This will involve the development of a marketplace for health service providers, but also digital health services. However, networking providers from the digital product and service sector is an absolute priority for the Zur Rose Group, so that patients of the future will be able to manage their own health management with products and digital solutions themselves.
